Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to impose a substantial global burden, with millions of cases and high mortality each year. Patients with bloodstream…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5 million hospital days and costs across the European Union (EU) and European Economic Area (EEA) economies €11.7 billion annually.
Around the World in HTA: Japan – An algorithmic approach to containing costs
14 April 2026
Japan’s health technology assessment (HTA) system uses algorithmic drug pricing and cost-effectiveness analysis to manage rising healthcare costs while maintaining universal access and innovation.
Masterclass: Cost-effectiveness thresholds in health technology assessment
8 April 2026
Join us for an in‑depth Masterclass that unpacks one of the most influential—and often misunderstood—elements of health technology assessment: cost‑effectiveness thresholds. Across the world, thresholds shape…
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
In the latest edition of our Insights series, Around the World in HTAs, we explore the HTA system in France. A special thanks to Salah Ghabri for his valuable support to write this note.
The case for adopting a broader perspective on value in Health Technology Assessment
3 March 2026
In this Whitepaper, we describe different perspectives that can be adopted in Health Technology Assessment (HTA), and some of the advantages and disadvantages of these different…
NICE’s new cost-effectiveness threshold: Significance, consequences, and unanswered questions
25 February 2026
NICE’s cost-effectiveness threshold will rise in April 2026, for the first time in 20 years. This raises important questions to consider as we approach the change and in the years that follow.
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
Biologics: Driving innovation in the treatment of multiple myeloma Biological medicines (biologics) have transformed the treatment landscape of multiple myeloma and cancer as a whole. The…
The commercial case for investing in ALS
13 November 2025
Amyotrophic lateral sclerosis (ALS) is a rare, rapidly progressive neurodegenerative disease with devastating clinical and economic consequences.